Novel histone post-translational modifications in Alzheimer’s disease: current advances and implications

Abstract

Alzheimer’s disease (AD) has a complex pathogenesis, and multiple studies have indicated that histone post-translational modifications, especially acetylation, play a significant role in it. With the development of mass spectrometry and proteomics, an increasing number of novel HPTMs, including lactoylation, crotonylation, β-hydroxybutyrylation, 2-hydroxyisobutyrylation, succinylation, and malonylation, have been identified. These novel HPTMs closely link substance metabolism to gene regulation, and an increasing number of relevant studies on the relationship between novel HPTMs and AD have become available. This review summarizes the current advances and implications of novel HPTMs in AD, providing insight into the deeper pathogenesis of AD and the development of novel drugs.

Epigenetic modifications of DNA and RNA in Alzheimer’s disease

“…Nonetheless, other DNA and RNA modifications not described in this review have been shown to or have the potential to influence AD pathology. Other reviews have explored the roles of histone modifications in AD and other neurological disorders, such as Park et al (2022) , Santana et al (2023) , and Qin et al (2024) .…”